Abstract：
OBJECTIVE: Extended release buprenorphine injection (INJ-BUP) has been available in the United States since 2018. INJ-BUP has the potential to positively impact opioid use disorder (OUD) treatment outcomes by providing additional treatment options . As one of the largest payers of OUD treatment in the US, Medicaid coverage is important for access and uptake of INJ-BUP. Uptake of INJ-BUP among Medicaid beneficiaries has not been described since 2019 and variation in uptake by state has not previously been explored. We aimed to measure prescribing of INJ-BUP for Medicaid beneficiaries since 2018, nationwide and by state.
METHODS: We analyzed State Drug Utilization Data from 2017 to 2022 and calculated the number of prescription fills for INJ-BUP and oral buprenorphine paid by Medicaid. To compare across states, we calculated the number of prescription fills per 100 Medicaid beneficiaries treated for OUD using data from Transformed Medicaid Statistical Information System Substance Use Disorder (T-MSIS SUD) Data Books. Data sources are publicly available.
RESULTS: The number of prescription fills for INJ-BUP paid by Medicaid increased from 4322 (0.1% of all buprenorphine prescription fills) in 2018 to 186 861 (2.0%) in 2022. Each year the increase in fills exceeded the prior year change, indicating accelerating uptake. There was notable variability across states.
CONCLUSIONS: The number of extended release buprenorphine injection prescriptions among US Medicaid beneficiaries treated for opioid use disorder increased from over 4000 prescriptions in 2018 to over 185 000 in 2022 but uptake is much less than observed in other countries over shorter time periods.
METHODS: We analyzed State Drug Utilization Data from 2017 to 2022 and calculated the number of prescription fills for INJ-BUP and oral buprenorphine paid by Medicaid. To compare across states, we calculated the number of prescription fills per 100 Medicaid beneficiaries treated for OUD using data from Transformed Medicaid Statistical Information System Substance Use Disorder (T-MSIS SUD) Data Books. Data sources are publicly available.
RESULTS: The number of prescription fills for INJ-BUP paid by Medicaid increased from 4322 (0.1% of all buprenorphine prescription fills) in 2018 to 186 861 (2.0%) in 2022. Each year the increase in fills exceeded the prior year change, indicating accelerating uptake. There was notable variability across states.
CONCLUSIONS: The number of extended release buprenorphine injection prescriptions among US Medicaid beneficiaries treated for opioid use disorder increased from over 4000 prescriptions in 2018 to over 185 000 in 2022 but uptake is much less than observed in other countries over shorter time periods.
摘要：
目的：丁丙诺啡缓释注射液（INJ-BUP）自2018年起在美国上市。INJ-BUP有可能通过提供额外的治疗选择对阿片类药物使用障碍（OUD）治疗结果产生积极影响。作为美国最大的OUD治疗付款人之一，医疗补助覆盖对于获得和吸收INJ-BUP很重要。自2019年以来，一直没有描述医疗补助受益人对INJ-BUP的摄取，以前也没有探索过国家摄取的变化。我们的目标是衡量自2018年以来医疗补助受益人的INJ-BUP处方，全国和各州。
方法：我们分析了2017年至2022年的州药物利用数据，并计算了由Medicaid支付的INJ-BUP和口服丁丙诺啡的处方填充数量。要跨各州进行比较，我们使用来自转化的医疗补助统计信息系统物质使用障碍(T-MSISSUD)数据簿的数据,计算了每100名接受OUD治疗的医疗补助受益人的处方配药数量.数据源是公开可用的。
结果：由Medicaid支付的INJ-BUP的处方填充数量从2018年的4322（占所有丁丙诺啡处方填充的0.1％）增加到2022年的186861（2.0％）。每年填充量的增加都超过了上一年的变化，表明加速吸收。各州之间存在显着差异。
结论：在接受阿片类药物使用障碍治疗的美国医疗补助受益人中，丁丙诺啡缓释注射处方的数量从2018年的4000多张增加到2022年的185000多张，但在较短的时间内，其摄入量远低于其他国家。
方法：我们分析了2017年至2022年的州药物利用数据，并计算了由Medicaid支付的INJ-BUP和口服丁丙诺啡的处方填充数量。要跨各州进行比较，我们使用来自转化的医疗补助统计信息系统物质使用障碍(T-MSISSUD)数据簿的数据,计算了每100名接受OUD治疗的医疗补助受益人的处方配药数量.数据源是公开可用的。
结果：由Medicaid支付的INJ-BUP的处方填充数量从2018年的4322（占所有丁丙诺啡处方填充的0.1％）增加到2022年的186861（2.0％）。每年填充量的增加都超过了上一年的变化，表明加速吸收。各州之间存在显着差异。
结论：在接受阿片类药物使用障碍治疗的美国医疗补助受益人中，丁丙诺啡缓释注射处方的数量从2018年的4000多张增加到2022年的185000多张，但在较短的时间内，其摄入量远低于其他国家。
